Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The form provides key information about the dealings of the exempt principal trader with Allergy Therapeutics plc. The form states that on November 8, 2023, Panmure Gordon (UK) Limited made purchases and sales of Allergy Therapeutics plc's 0.1p ordinary shares. The form provides the total number of securities bought and sold, as well as the highest and lowest prices per unit paid and received.
The form does not disclose any cash-settled derivative transactions or stock-settled derivative transactions, including options, related to Allergy Therapeutics plc. It also states that there are no indemnity or option arrangements, agreements, or understandings between Panmure Gordon (UK) Limited and any party to the offer or any person acting in concert with a party to the offer. Additionally, there are no agreements, arrangements, or understandings relating to options or derivatives.
The disclosure was made in accordance with Rule 8 of the Takeover Code and must be made to a Regulatory Information Service. The contact person for the disclosure is Freddie Wooding, and the telephone number provided is +44 (0)20 7886 2969. The Panel's Market Surveillance Unit is also available for consultation regarding the Code's dealing disclosure requirements.
No further information about Allergy Therapeutics plc or its operations is provided in the news.